Skip to main content

Advertisement

Table 3 Multivariate analysis (Cox regression) for the overall survival and time to leukemia transformation in MDS patients

From: Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome

  Overall survival Time to leukemia transformation
Variable HR (95% CI) P value* HR (95% CI) P value*
FAB-defined MDS patients
 Age > 65 1.512 (1.134–2.016) 0.005 0.656 (0.417–1.031) 0.067
 Male vs female 1.104 (0.818–1.491) 0.517 0.967 (0.615–1.521) 0.886
 IPSS-R higher risk# 3.239 (2.199–4.772) < 0.001 5.258 (2.639–10.477) < 0.001
DNMT3A mutation 1.733 (1.118–2.688) 0.014 3.088 (1.574–6.056) 0.001
ASXL1 mutation 2.010 (1.434–2.818) < 0.001 3.396 (2.075–5.556) < 0.001
EZH2 mutation 1.019 (0.597–1.741) 0.945 0.885 (0.416–1.880) 0.750
TET2 mutation 1.416 (0.974–2.059) 0.068 1.398 (0.739–2.644) 0.303
RUNX1 mutation 1.134 (0.773–1.663) 0.519 1.751 (1.026–2.987) 0.040
SF3B1 mutation 1.071 (0.679–1.691) 0.767 1.392 (0.699–2.771) 0.347
TP53 mutation 8.254 (5.338–12.762) < 0.001 6.653 (3.183–13.909) < 0.001
2016 WHO-defined MDS patients
 Age > 65 1.649 (1.173–2.319) 0.004 0.731 (0.444–1.203) 0.217
 Male vs female 1.184 (0.822–1.705) 0.364 0.988 (0.596–1.637) 0.963
 IPSS-R higher risk# 3.840 (2.432–6.063) < 0.001 5.078 (2.390–10.787) < 0.001
DNMT3A mutation 1.800 (1.080–3.000) 0.024 2.360 (1.129–4.933) 0.022
ASXL1 mutation 1.830 (1.208–2.774) 0.004 3.596 (2.092–6.182) < 0.001
EZH2 mutation 1.196 (0.536–2.668) 0.662 0.927 (0.299–2.875) 0.896
TET2 mutation 1.367 (0.841–2.223) 0.208 1.420 (0.643–3.139) 0.386
RUNX1 mutation 1.165 (0.723–1.876) 0.531 1.426 (0.753–2.702) 0.276
SF3B1 mutation 1.251 (0.743–2.153) 0.387 1.423 (0.613–3.305) 0.412
TP53 mutation 8.517 (5.005–14.492) < 0.001 8.885 (4.077–19.365) < 0.001
  1. Abbreviation: HR, hazard ratio; CI, confidence interval; IPSS-R, Revised international prognostic scoring system
  2. *P value < 0.05 was considered significant
  3. #IPSS-R higher risk: patients with intermediate, high, and very high risk versus others